|
|
|
|
Sinovacs Revenue and Profit Slide Lower In Q3
SVA Headline Feed Sector Feeds: Sinovac Biotech (AMEX: SVA) had the unhappy task of telling investors that revenue and profits declined in Q3.In the quarter, its flagship hepatitis A vaccine, Healive, sold 28% fewer doses; AnFlu, the flu...
|
|
|
Update module 1456: How to treat childhood infections
How to distinguish between and treat six common childhood infections: measles, chickenpox, rubella, mumps, whooping cough and meningitis Key points Measles, rubella, whooping cough, mumps, meningococcal meningitis and septicaemia are...
|
|
|
Calls for a more flexible approach to vaccine funding
Governments should take a broader perspective - including quality-of-life impacts - when considering whether to fund vaccines, according to a paper from the University of New South Wales (UNSW).A national vaccination program would help...
|
|
|
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting MARLBOROUGH, Mass.-(Business Wire)-November 10, 2008 -...
|
|
|
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented
Sepracor (Nasdaq: SEPR) today announced the presentation of Phase III study data for ALVESCO (ciclesonide) HFA Inhalation Aerosol and Phase I data for a ciclesonide HFA MDI nasal aerosol formulation for the treatment of allergic rhinitis.
|
|
|
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA
www.sepracor.com- Sepracor Inc.Jonae R. Barnes, 508-481-6700 Sr. Vice President, Investor Relations and Corporate Communications Sepracor (Nasdaq: SEPR) today announced the presentation of Phase III study data for ALVESCO(R) ...
|
|
|
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented
MARLBOROUGH, Mass.- (Business Wire) Sepracor (Nasdaq: SEPR) today announced the presentation of Phase III study data for ALVESCO (ciclesonide) HFA Inhalation Aerosol and Phase I data for a ciclesonide HFA MDI nasal aerosol formulation for...
|
|
|
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting 2008-11-1007:48ET - News Release Phase III results show...
|
|
|
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented
MARLBOROUGH, Mass.(Business Wire) -- Sepracor (Nasdaq: SEPR) today announced the presentation of Phase III study data for ALVESCO(R) (ciclesonide) HFA Inhalation Aerosol and Phase I data for a ciclesonide HFA MDI nasal aerosol formulation...
|
|
|
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented
Sepracor (Nasdaq: SEPR) today announced the presentation of Phase III study data for ALVESCO (ciclesonide) HFA Inhalation Aerosol and Phase I data for a ciclesonide HFA MDI nasal aerosol formulation for the treatment of allergic rhinitis.
|
|
|
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented
-Sepracor (Nasdaq: SEPR) today announced the presentation of Phase III study data for ALVESCO (ciclesonide) HFA Inhalation Aerosol and Phase I data for a ciclesonide HFA MDI nasal aerosol formulation for the treatment of allergic rhinitis.
|
|
|
US-based MSD pharma to hire 1,500 people in India
(Asia Pulse Data Source via COMTEX) -- MRK | Quote | Chart | News | PowerRating -- Even as global financial slowdown is forcing companies to retrench jobs, MSD Pharmaceuticals-- a subsidiary of US-based Merck & Co today said it will...
|
|
|
MSD to hire 1,500 people in India
Chandigarh, Nov 5 (PTI) Even as global financial slowdown is forcing companies to retrench jobs, MSD Pharmaceuticals -- a subsidiary of US-based Merck & Co -- today said it will employ 1,500 people in the next two years to strengthen...
|
|
|
MSD Pharma to hire 1,500 people in India
17:35 IST Even as global financial slowdown is forcing companies to retrench jobs, MSD Pharmaceuticals, a subsidiary of US-based Merck & Co, today said it will employ 1,500 people in the next two years to strengthen its sales and...
|
|
|
Most adults not up to date on their vaccinations
Most adults are not up to date on their vaccinations, says a new report from Harvard Medical School.The report, Viruses and Infectious Diseases, describes how fast-adapting viruses pose an advancing threat to human health and urges adults...
|
|
|
New Vaccines for Adults: Which Do You Need?
Newswise Most adults are not up to date on their vaccinations, says a new report from Harvard Medical School.The report, Viruses and Infectious Diseases, describes how fast-adapting viruses pose an advancing threat to human health and...
|
|
|
HPV vaccine reaches one in
ave rolled up their sleeves for the relatively new vaccine against cervical cancer, federal health officials said Thursday.The figures represent the government's first substantial study of vaccination rates for the Gardasil vaccine -...
|
|
|
New Vaccines for Adults: Which do You Need? From Harvard Medical School
BOSTON, Nov.4, 2008Most adults are not up to date on their vaccinations, says a new report from Harvard Medical School. The report, Viruses and Infectious Diseases, describes how fast-adapting viruses pose an advancing threat to human...
|
|
|
New Vaccines for Adults: Which Do You Need?
The new report explains how viruses and other infections affect the body, and what adults should do to protect themselves.It warns adults not to assume that the vaccines they received as children will protect them for life. Here are...
|
|
|
New Vaccines for Adults: Which Do You Need?
BOSTON The new report explains how viruses and other infections affect the body, and what adults should do to protect themselves.It warns adults not to assume that the vaccines they received as children will protect them for life. Here...
|
|
|
1 in 4 US teen girls got cervical cancer shot
ATLANTA ---- One in four teen girls have rolled up their sleeves for the relatively new vaccine against cervical cancer, federal health officials said last month.The figures represent the government's first substantial study of...
|
|
|
Funding of drugs: do vaccines warrant a different approach?
The Lancet Infectious Diseases, Current Issue, Volume 8, Number 11, November 2008 The Lancet Infectious Diseases 2008; 8:727-733 Personal View Dr Philippe Beutels PhD a b , Prof Paul A Scuffham PhD c and Prof C Raina MacIntyre PhD d Summary...
|
|
|
MerckEURs Durham facility on road to completion
Merck & Co has completed start-up activities at its vaccine manufacturing plant in Durham, North Carolina, which is intended to further the companys ambitions in the sector.The validation of production processes has also commenced at...
|
|
|
Merck Dedicates Durham Vaccine Manufacturing Facility in Honor of Merck Scientist Maurice R. Hilleman, Ph.D
Merck has announced that its Durham, North Carolina, vaccine manufacturing facility has completed start-up activities and is beginning to validate production processes, a major step toward regulatory approval and licensure of the new...
|
|
|
US antiterrorism rules restrict vaccine exports
(CIDRAP News) - A recent Associated Press (AP) report revealed that, in the name of preventing biological attacks, the United States has rules barring the exportation of vaccines for avian influenza, smallpox, yellow fever, and many other...
Centre For Infectious Disease Research and Policy:
Oct 17 2008 10:23PM
Matching: chickenpox
|
Find similar documents
|
|
